S&P Futures
5,887.75 -4.75 (-0.08%) Dow Futures
43,044.00 -125.00 (-0.29%) Nasdaq Futures
20,520.50 -21.50 (-0.10%) Russell 2000 Futures
2,244.70 -1.50 (-0.07%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,763.70 +3.90 (+0.14%)
After hours:
- GlobeNewswire
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced new findings from its Phase 2 ARCHER study for ANX0
- Simply Wall St.
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Annexon ( NASDAQ:ANNX...
- GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new non-execut
